Kelowna, British Columbia - September 29, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced  at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share. In addition, in a concurrent private placement, the Company issued unregist ...

 Kelowna, British Columbia – TheNewswire - September 26, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private ...

Core Insights - The study conducted by Lexaria Bioscience Corp. indicates that the DehydraTECH processing of semaglutide enhances its brain biodistribution compared to conventional formulations, potentially improving safety and efficacy [1][3][6] Study Findings - The primary objective of the study was to assess whether DehydraTECH processing significantly improves the biodistribution of semaglutide [2] - The DehydraTECH-FTS composition showed a higher apparent trend in brain biodistribution across all tested doses, with the 5mg DehydraTECH-FTS achieving greater brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent [3][5] - Fluorescent imaging revealed that all three DehydraTECH doses tested had higher fluorescence in key brain regions compared to naïve and vehicle groups, while only the highest dosage of Rybelsus® surpassed these groups [5] Mechanism and Implications - The study suggests that enhanced brain biodistribution may be linked to the pharmacodynamic performance of GLP-1 drugs, which are known to interact with brain neurochemistry [6][7] - Semaglutide's ability to regulate body weight through GLP-1 receptor activation in the brain could lead to appetite suppression without common side effects like nausea [6] - Lexaria's findings may support the development of safer and more effective GLP-1 drugs in the future [8] Research Methodology - The preclinical pilot study involved Sprague Dawley rats and utilized non-invasive whole-body imaging and ex vivo organ analysis to evaluate the biodistribution of oral semaglutide [9][12] - A total of 25 male rats were used, with 22 allocated for dosing and 3 as untreated controls, examining both DehydraTECH and Rybelsus® equivalent compositions [12][13] Technology Overview - DehydraTECH is a patented drug delivery platform that enhances the absorption and effectiveness of various drugs, including those that cross the blood-brain barrier [14]

Core Viewpoint - Lexaria Bioscience Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8th to September 10th, 2025, highlighting its innovative drug delivery technology, DehydraTECH [1][3]. Company Overview - Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on improving the way drugs enter the bloodstream through oral delivery [1][3]. - The company operates a licensed in-house research laboratory and holds a strong intellectual property portfolio with 50 patents granted and additional patents pending worldwide [3]. Technology Highlights - DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform that enhances bio-absorption, reduces side effects, and improves drug delivery across the blood-brain barrier [3].

Core Insights - Lexaria Bioscience Corp. has received 2 new international patents, increasing its total patent portfolio to 50 [1][2] - The new patents include one for treating epilepsy and another for sublingual delivery of nicotine, enhancing Lexaria's intellectual property protection [2][3] - The epilepsy drug market was valued at US$9.5 billion in 2023 and is projected to exceed US$15 billion by 2032, indicating significant growth potential [4] - The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at a rate of 26% per year until at least 2030 [5] Company Developments - Lexaria's new patent for epilepsy treatment broadens its intellectual property protection outside the USA, where it already holds 6 existing patents [2] - The new patent for sublingual delivery of nicotine adds to existing patents in the USA and Canada, further solidifying Lexaria's position in the nicotine market [3] - The new patents are seen as a strategic move to enhance commercial opportunities within the pharmaceutical industry and to build long-term value for shareholders [2] Market Context - Approximately 50 million people in the US are affected by epilepsy, highlighting a substantial patient population for potential treatments [4] - The nicotine pouch market, where Lexaria's DehydraTECH™ technology has shown absorption benefits, is expected to reach US$25.4 billion in revenue by 2030 [5] - Lexaria's DehydraTECH™ technology improves the delivery of active pharmaceutical ingredients, demonstrating increased bio-absorption and effectiveness across the blood-brain barrier [6]

Core Insights - Lexaria Bioscience Corp. will participate in the BIO International Convention in Boston from June 16-19, 2025, aiming to advance discussions with potential partners and investors [1][2] Company Overview - Lexaria is a global innovator in drug delivery platforms, specifically through its patented DehydraTECH® technology, which enhances drug absorption and reduces side effects [4] - The company holds 48 granted patents and has additional patents pending worldwide, showcasing a strong intellectual property portfolio [4] Event Participation - The BIO International Convention is the largest biotechnology convention globally, featuring over 1,500 exhibitors and 20,000 attendees, providing a platform for networking and collaboration [2] - Lexaria is arranging one-on-one meetings with corporate leaders in sectors such as weight loss, diabetes, and hypertension, with limited meeting slots still available [3]

Core Insights - Lexaria Bioscience Corp. has entered into a Material Transfer Agreement (MTA) with a pharmaceutical company to evaluate its DehydraTECH technology in pre-clinical studies [1][2] - Initial pre-clinical studies have been completed, focusing on pharmacokinetics in animals, but results will not be disclosed [2] - Lexaria is preparing for strategic discussions with the pharmaceutical company's clinical development team regarding potential human clinical studies [3] Company Overview - Lexaria's DehydraTECH is a patented drug delivery platform that enhances the absorption of various drugs through oral delivery, aiming to improve bio-absorption and reduce side effects [4] - The company holds a strong intellectual property portfolio with 48 patents granted and additional patents pending globally [4]

Core Viewpoint - Lexaria Bioscience Corp. successfully closed a registered direct offering, raising $2.0 million by selling 2,000,000 shares at $1.00 each, minimizing dilution for existing shareholders by avoiding the issuance of new warrants, except for pre-funded warrants [1][2][3]. Group 1: Offering Details - The offering involved a single institutional investor purchasing 2,000,000 shares of common stock or pre-funded warrants at a price of $1.00 per share [1]. - The gross proceeds from the offering were $2.0 million before deducting placement agent fees and other expenses [3]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [3]. Group 3: Company Background - Lexaria operates a patented drug delivery platform, DehydraTECH™, which enhances the absorption of various drugs through oral delivery [6]. - The company holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide [6].